Comparison
Fevipiprant vs Bimatoprost
Oral DP2 antagonism vs. topical prostamide analog — two routes to manipulating the prostaglandin axis for hair.
Fevipiprant
DP2 / CRTH2 Antagonist
Bimatoprost
Prostamide / PGF2α Analog
Effectiveness Profile
At a Glance
| Fevipiprant | Bimatoprost | |
|---|---|---|
| Type | Hair | Hair |
| Legal status | Research | Rx-Only |
| Half-life | ~20 hours | ~45 min plasma; ~2 h aqueous humor |
| Preferred route | Oral | Topical |
| Dose frequency | once-daily | once-daily |
| Beginner dose | 150–150 mg | 15–30 mcg |
| Intermediate dose | 150–300 mg | 30–60 mcg |
| Advanced dose | 300–450 mg | 60–90 mcg |
| Cycle length | 26–52 wks | 12–52 wks |
| Bioavailability | 80% | — |
| Time to peak | 2h | 1.5h |
| Active duration | 24h | 24h |
| Storage | Room temperature, dry, protected from light | 15–25°C room temperature; refrigerate after opening for extended shelf life |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Fevipiprant wins for experimental mechanistic coverage in androgenic alopecia, systemically targeting the PGD2/DP2 blockade that no existing FDA-approved hair compound does; oral convenience for those after whole-scalp distribution; and a clean systemic safety profile from phase 3 asthma studies at up to 450 mg q.d.
Bimatoprost wins for proven efficacy in eyelash and eyebrow growth (photographic, double-digit percent gains within 16 weeks); accessible, measured topical protocols; and rapid, obvious aesthetic returns for facial hair enhancement. Sourcing is trivial with multiple generic options, and results are reproducible in a cosmetic context.
Pick A or B?
Pick Fevipiprant if:
- The goal is experimenting with novel oral interventions for scalp androgenic alopecia, especially for those who have plateaued on finasteride/minoxidil.
- A scalp-wide, systemic approach is prioritized over targeted topical gains.
- There is interest in combining diverse mechanisms (stacking with 5-AR inhibitors, minoxidil, and microneedling) for potential additive outcomes.
- Long timelines and experimental outcomes are accepted as part of the protocol.
- Topical regimens are not preferred or tolerated.
Pick Bimatoprost if:
- Quick, visible enhancement of eyelashes or eyebrows is the primary goal (25%+ length and significant thickness/darkness at 4 months).
- Precision application and localized growth matter more than scalp-wide effect.
- Research protocols are focused on facial aesthetics rather than scalp density.
- A well-characterized, FDA-approved cosmetic protocol is desired, with easy access to generics.
- Abandoning the protocol and reverting to baseline is acceptable if needed (results regress within weeks after cessation).